U.S. FDA Has Approved Several Colon and Rectal Cancer Drugs to Treat Colon and Rectal Cancer

Colon and Rectal Cancer Drugs
Colon and Rectal Cancer Drugs

Colon and Rectal Cancer Drugs are used to treat colon and rectal cancer. Cancer that begins in the colon is called colon cancer, while cancer in the rectum is known as rectal cancer. Colorectal cancer starts in the colon or rectum. Colon and rectal cancer are often grouped together because they have many features in common. The colon and rectum are parts of the large intestine. The colon is found below the stomach. The rectum is a short tube connected to the colon. Together, the colon and rectum are about 2 meters (6.5 feet) long.

Treatment for colorectal cancer (colon and rectal cancer) usually involves surgery to remove cancer. Other treatments might also be recommended, such as chemotherapy and radiation therapy (radiotherapy). Colon and Rectal Cancer Drugs can be used to treat colon cancer. Some drugs commonly used for colorectal cancer include 5-Fluorouracil (5-FU), Trifluridine and tipiracil (Lonsurf), Irinotecan (Camptosar), Oxaliplatin (Eloxatin), and Capecitabine (Xeloda). These drugs can be given by mouth or directly into the blood.

Whereas, drugs approved for rectal cancer include 5Fluorouracil Injection, -FU (Fluorouracil Injection), Eloxatin (Oxaliplatin), Erbitux (Cetuximab), Cetuximab, Cyramza (Ramucirumab), Capecitabine, Avastin (Bevacizumab), Bevacizumab, Camptosar (Irinotecan Hydrochloride), and Trifluridine and Tipiracil Hydrochloride, among others. There are more colon cancer and rectal cancer drugs that are not listed here. There is an increasing Demand for Colon and Rectal Cancer Drugs Market due to increasing prevalence of colon and rectal cancer worldwide.

In the United States, colorectal cancer is the third leading cause of cancer-related deaths in men and in women, and the second most common cause of cancer deaths in men and in women. For example, according to the American Cancer Society, in 2022, an estimated 106,180 new cases of colon cancer and 44,850 new cases of rectal cancer will be diagnosed in the U.S.

Comments

Post a Comment

Popular posts from this blog

Sarcopenia Treatment; Training and Physical Exercise Is Key to Counteract Sarcopenia

Image
Sarcopenia Treatment A primary Sarcopenia Treatment is exercise. Researchers have identified resistance training as the specific form of exercise that is most beneficial to individuals with sarcopenia. At present, resistance exercise, protein supplementation, and vitamin D have been established as the basic treatment of sarcopenia. Recent clinical trials on sarcopenia therapies such as physical exercise, nutraceutical, and pharmaceutical interventions have revealed that exercise is the only effective strategy shown to alleviate sarcopenia. Sarcopenia refers to a loss of muscle mass specifically related to aging. It's normal to lose some muscle mass as people age. Sarcopenia has been defined as an age-related, involuntary loss of skeletal muscle mass and strength. Although aging is the main cause of sarcopenia, some other factors contribute to the loss of muscle mass. Getting little or no physical activity on a regular basis puts people at an increased risk of developing sarcopenia
Read more

Increasing Developments by Key Players Are Expected To Augment the Growth of the Global Digital Pathology Market

Image
 Digital Pathology Digital Pathology Market , by Product Type (Image Analysis Software, Scanner {Bright Field Scanner, Fluorescence Scanner}, Services {Installation & Integration, Maintenance Services, Consulting Services}), by Therapeutic Area (Oncology, Hematology, Autoimmune Disorder, Dermatology, and Others), by Technology (Immunohistochemistry, ISH & FISH, Immunofluorescence and others) End User (Pharmaceutical & Biotechnology Companies, Diagnostic Labs, Hospital Laboratories, and Others), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)- Size, Share, Outlook, and Opportunity Analysis, 2023 - 2030. The global Digital Pathology Market is anticipated to reach an estimated value of US$ 884.4 million in 2023 and is projected to grow at a CAGR of 12.2% from 2023 to 2030. Market Overview: Digital pathology refers to the practice of digitizing glass slides containing tissue samples and analyzing them using digital imaging technology
Read more

Patient-Centered Medical Home; Is Used To Offer High-Standard, Inexpensive Primary Care

Image
Patient-Centered Medical Home The Patient-Centered Medical Home is a care model in which individuals are involved in a direct association with a chosen physician who organizes a supportive team of hospital experts, takes cooperative accountability for the comprehensive incorporated care offered to the patient, and sponsors and arranges suitable care with other professional physicians and community sources as per requirements. Use of PCMH develop disciplinary care teams to enhance care management and care administration of patient populaces focusing to increase safety, efficacy and standard in patient care. PCMH practices can enhance care and take benefits of private or public inducement payments that are offered to patients. The Patient Protection and Affordable Care Act (ACA) provides extra federal expenditure to regions for health homes helping Medicaid receivers. Supplier groups and hospitals can visit their federal and state officials and private insurers’ websites for data on exp
Read more